ASSOCIATION OF POSTPRANDIAL BLOOD SUGAR WITH HYPERCOAGULABILITY IN COMPARISON TO FASTING BLOOD SUGARS IN DIABETIC AND HEALTHY PATIENTS: A CROSS-SECTIONAL STUDY

Sri Ramulu Kadiyala; Karthik Rao; Nr Rao; Ram Bhat; Jayaprakash Rao; Navin Patil; Balaji O

doi:10.22159/ajpcr.2017.v10i7.18806

Authors

Sri Ramulu Kadiyala Department of Cardiology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India
Karthik Rao Department of Internal Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka, India.
Nr Rao Consultant, Anugraha Medical Centre, Udupi, Karnataka, India.
Ram Bhat Department of Internal Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka, India
Jayaprakash Rao Department of Internal Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka, India
Navin Patil Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India.
Balaji O Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i7.18806

Keywords:

Hypercoagulation, Fibrinogen levels, Clotting factors, Diabetes mellitus

Abstract

Objective: The aim of this study was to find the association of postprandial blood glucose with hypercoagulability in comparison to fasting blood sugars(FBS) in diabetic and healthy patients.

Methods: The present study involved a total of 156 patients, of which 78 were taken as cases (diabetics) and other 78 as controls (non-diabetics). Laboratory analysis included prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen assay done along with fasting, and postprandial sugars.

Results: Platelets in diabetics and healthy controls were in normal range. Decrease in PT and partial thromboplastin time was noted in diabetics compared to non-diabetic controls. Fibrinogen levels were increased in cases compared to controls. Changes in PT values were more significant with postprandial blood sugar (PPBS) levels when compared to FBS levels, and APTT follows the same pattern with more in PPBS levels and FBS levels in diabetics. PPBS showed elevated fibrinogen when compared to FBS in diabetics as well as non-diabetics.

Conclusion: Type 2 diabetes mellitus is a hypercoagulable state as proven by the following results of our study.

Downloads

Download data is not yet available.

References

Tripathy B, Chandalia HB, Das AK, Rao P. RSSDI: Textbook of diabetes mellitus: JP Medical Ltd; 2012.

Cubbon RM, Wheatcroft SB, Grant PJ, Gale CP, Barth JH, Sapsford RJ, et al. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. European heart journal. 2007;28(5):540-5.

Carr ME. Diabetes mellitus: a hypercoagulable state. Journal of diabetes and its complications. 2001;15(1):44-54.

Grant PJ. Diabetes mellitus as a prothrombotic condition. Journal of internal medicine. 2007;262(2):157-72.

Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The New England journal of medicine. 1998;339(4):229-34.

Stratmann B, Tschoepe D. Atherogenesis and atherothrombosis--focus on diabetes mellitus. Best practice & research Clinical endocrinology & metabolism. 2009;23(3):291-303.

Grant PJ. Inflammatory, atherothrombotic aspects of type 2 diabetes. Current medical research and opinion. 2005;21 Suppl 1:S5-12.

Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. The New England journal of medicine. 2001;345(19):1359-67.

Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39(12):1577-83.

Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43(8):960-7.

Borsey DQ, Prowse CV, Gray RS, Dawes J, James K, Elton RA, et al. Platelet and coagulation factors in proliferative diabetic retinopathy. Journal of clinical pathology. 1984;37(6):659-64.

Erem C, Hacihasanoglu A, Celik S, Ovali E, Ersoz HO, Ukinc K, et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2005;14(1):22-30.

Madan R, Gupt B, Saluja S, Kansra UC, Tripathi BK, Guliani BP. Coagulation profile in diabetes and its association with diabetic microvascular complications. The Journal of the Association of Physicians of India. 2010;58:481-4.

Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes care. 2002;25(6):1055-9.

Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. The American journal of cardiology. 2003;92(11):1362-5.

Acang N, Jalil FD. Hypercoagulation in diabetes mellitus. The Southeast Asian journal of tropical medicine and public health. 1993;24 Suppl 1:263-6.

Zhao Y, Zhang J, Zhang J, Wu J. Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values. PloS one. 2011;6(1):e16470.

Weiler H, Isermann BH. Thrombomodulin. Journal of thrombosis and haemostasis : JTH. 2003;1(7):1515-24.

Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes care. 1999;22 Suppl 3:C25-30.

Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Annals of medicine. 1996;28(4):371-80.

Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia. 1988;31(12):889-91.

Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel L, Motz E, et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia. 1996;39(4):469-73.

Silveira A, Karpe F, Johnsson H, Bauer KA, Hamsten A. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arteriosclerosis, thrombosis, and vascular biology. 1996;16(11):1333-9.

Gasser JA, Betteridge DJ. Lipids and thrombosis. Bailliere's clinical endocrinology and metabolism. 1990;4(4):923-38.

Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes care. 2000;23(12):1830-4.

Bruttomesso D, Iori E, Kiwanuka E, Zanetti M, Pianta A, Vettore M, et al. Insulin infusion normalizes fasting and post-prandial albumin and fibrinogen synthesis in Type 1 diabetes mellitus. Diabetic medicine : a journal of the British Diabetic Association. 2001;18(11):915-20.